Form D · Biotechnology
Endeavor Biomedicines, Inc.
San Diego, CA · CIK 0001909364
Offering snapshot reported May 3, 2024 · SEC filing
- Reported sold
- $133M Offering amount: $133M
- Investors reported
- 32 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 22, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 3, 2024 | Initial | $132,583,908 | No comparison | 32 | SEC filing |
| Feb 7, 2022 | Initial | $89,119,331 | No comparison | 16 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-512326
Source: Form D, filed May 3, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Bernard Davitian | Director |
| Miguel De Los Rios | Executive |
| Patrick G. Enright | Director |
| John Hood | Director, Executive |
| Enoch Kariuki | Executive |
| Chris Krueger | Executive |
| Wing Cheong Lam | Director |
| Monal Mehta | Director |
| Raghu Saripalli | Executive |
| Karan Takhar | Director |
| Vishaal Turakhia | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
12707 High Bluff Drive, Suite 300
San Diego, CA, 92130
San Diego, CA, 92130